Incongruity of imaging using fluorescent 2-DG conjugates compared to 18F-FDG in preclinical cancer models

Jen Chieh Tseng, Yuchuan Wang, Pallab Banerjee, Andrew L. Kung

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: We compared the use of near-infrared conjugates of 2-deoxyglucose (NIR 2-DG) to 2-deoxy-2-[18 F]fluoro-D-glucose (18 F-FDG) for the purposes of imaging tumors, as well as response to therapy. Procedures: Uptake of both 18 F-FDG and NIR 2-DG within gastrointestinal stromal tumor xenografts were imaged before and after nilotinib treatment. Confocal microscopy was performed to determine NIR 2-DG distribution in tumors. Results: Treatment with nilotinib resulted in a rapid reduction in 18 F-FDG uptake and reduced tumor cell viability which was predictive of long-term antitumor efficacy. In contrast, optical imaging with NIR 2-DG probes was unable to differentiate control from niltonib-treated animals, and microscopic analysis revealed no change in probe distribution as a result of treatment. Conclusions: These results suggest that conjugation of large bulky fluorophores to 2-DG disrupts the facilitated transport and retention of these probes in cells. Therefore, optical imaging of NIR 2-DG probes cannot substitute for 18 F-FDG positron emission tomography imaging as a biomarker of tumor cell viability and metabolism.

Original languageEnglish (US)
Pages (from-to)553-560
Number of pages8
JournalMolecular Imaging and Biology
Volume14
Issue number5
DOIs
StatePublished - Oct 2012

Keywords

  • 2-Deoxyglucose (2-DG)
  • F-FDG
  • Fluorescent imaging
  • Gastrointestinal tumor (GIST)
  • MicroPET
  • Near-infrared
  • Nilotinib
  • Optical imaging
  • Tumor xenograft

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Incongruity of imaging using fluorescent 2-DG conjugates compared to <sup>18</sup>F-FDG in preclinical cancer models'. Together they form a unique fingerprint.

Cite this